title: [Effects of restrictions on use of vancomycin in a German university hospital].
abstract: BACKGROUND
  Recently, increasing antibiotic resistance has been observed among gram-positive bacteria. However, only few isolates were found to be resistant against glycopeptides. Therefore, internationally accepted guidelines recommend a restricted use of vancomycin and other glycopeptide antibiotics in order to prevent the development of resistance against these clinically important antibiotics. In many countries, the hospital pharmacies play a key role in control and reinforcement of antibiotic formulary restrictions. In Germany, however, the hospital pharmacies usually do not take over such control functions, and most wards keep a stock of regularly used drugs including antibiotics, which makes reinforcement of restrictions difficult.
  
  
  METHODS
  In an attempt to achieve a restriction of vancomycin use, the pharmacy of our university hospital was advised to deliver vancomycin to the wards only on request with a special order form signed by an attending, individually for every patient who should receive vancomycin. The efficacy of this restriction measure was evaluated in 3-month periods before and after the restriction became effective.
  
  
  RESULTS
  Hospitalwide, this led to a 20.1% reduction of i.v. vancomycin and an 85.7% reduction of oral vancomycin use per 1000 patient days. If the hematology/oncology units were not considered, the reduction of i.v. vancomycin use was 41.8%, and the total use after the restriction 24.2 g per 1000 patient days. Microbiology results which justified the use of vancomycin decreased by 8.3% (10.9% hematology/oncology units not considered) between the 2 observation periods. Assuming a 7-day mean course of i.v. vancomycin therapy, the empirical use of i.v. vancomycin decreased from 39.9% to 8% after the restriction had been instituted.
  
  
  CONCLUSIONS
  Allowing only experienced physicians (attendings) to decide on the use of vancomycin therapy, proved in our experience to be an effective measure to reduce unnecessary vancomycin use.
authors.affiliation: Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg. thomas.glueck@klinik.uni-regensburg.de
authors.forename: T
authors.initials: T
authors.lastname: Glück
authors.forename: H J
authors.initials: HJ
authors.lastname: Linde
authors.forename: E
authors.initials: E
authors.lastname: Wiegrebe
authors.forename: N
authors.initials: N
authors.lastname: Lehn
authors.forename: M
authors.initials: M
authors.lastname: Reng
authors.forename: J
authors.initials: J
authors.lastname: Schölmerich
mesh_terms: D004363:Drug Utilization / Q000706:statistics & numerical data; D017723:Drug Utilization Review; D004335:Drug and Narcotic Control / Q000379:methods; D005500:Follow-Up Studies; D005572:Formularies, Hospital as Topic; D005858:Germany; D006785:Hospitals, University / Q000458:organization & administration*; D006801:Humans; D014640:Vancomycin / Q000627:therapeutic use*; D020713:Vancomycin Resistance
chemical_list: D014640:Vancomycin